Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Solvay U.S. CEO

Executive Summary

The U.S. division of Solvay Pharmaceuticals names Laurence Downey CEO, effective Jan. 1, 2006. Downey, who served as president and CEO of Solvay Pharma Inc. in Canada since 1999, succeeds Harold Shlevin who was promoted to the position of VP-regulatory safety, quality strategies and external affairs within Solvay Pharmaceuticals...

You may also be interested in...



Solvay U.S. CEO (correction)

Former CEO of the U.S. division of Solvay Pharmaceuticals Harold Shlevin was promoted to the position of global senior VP-regulatory, safety and quality strategies and external affairs for the global Solvay Pharmaceuticals organization. "The Pink Sheet" incorrectly reported his new position (1"The Pink Sheet" Jan. 9, 2006, In Brief)...

TriSalus Thinks Its Drug/Device Strategy Can Optimize IO Regimens

The firm licensed the TLR9 agonist SD-101 from Dynavax to test with its pressure-enabled drug delivery technology in liver and pancreatic settings where immuno-oncology has shown moderate efficacy or less.

Advisory Committee For Biogen's Aducanumab Will Test US FDA's 'Substantial Evidence' Flexibility

Given inconsistent study results, robustness of the efficacy evidence is expected to be key focus of the 6 November meeting of the Peripheral and Central Nervous System Drugs Advisory Committee; review could put a December 2019 guidance on the ‘substantial evidence’ standard to the test and offer insight into the amount of flexibility the agency is willing to exercise for neurodegenerative diseases with high unmet need.

UsernamePublicRestriction

Register

MT142313

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel